Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Expands By 79.2%

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 270,200 shares, an increase of 79.2% from the January 31st total of 150,800 shares. Based on an average daily volume of 540,300 shares, the short-interest ratio is currently 0.5 days. Currently, 10.2% of the shares of the stock are sold short.

Traws Pharma Stock Performance

TRAW stock traded down $0.05 on Friday, hitting $3.31. 72,130 shares of the company’s stock traded hands, compared to its average volume of 96,156. Traws Pharma has a 1-year low of $3.06 and a 1-year high of $27.50. The firm has a market cap of $12.08 million, a PE ratio of -0.02 and a beta of 1.10. The stock’s fifty day moving average is $7.26.

Institutional Investors Weigh In On Traws Pharma

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC purchased a new stake in shares of Traws Pharma in the 4th quarter valued at approximately $89,000. Renaissance Technologies LLC purchased a new stake in shares of Traws Pharma in the 4th quarter valued at approximately $89,000. Geode Capital Management LLC purchased a new stake in shares of Traws Pharma in the 4th quarter valued at approximately $185,000. Boothbay Fund Management LLC purchased a new stake in shares of Traws Pharma in the 4th quarter valued at approximately $252,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Traws Pharma in the 4th quarter valued at approximately $666,000. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.